We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

By LabMedica International staff writers
Posted on 30 Apr 2025

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. More...

However, around 1 in 5 individuals with myeloma have a high-risk form of the disease, which is marked by an earlier relapse following initial treatment. This leads to a shorter survival period, typically just 2-3 years. A key challenge for clinicians is predicting when relapse will occur so that patients can be treated with effective alternative therapies before the disease advances. Now, a research team is evaluating a new mass spectrometry-based monitoring technique to determine its ability to predict and identify early relapses of the disease.

The introduction of more effective therapies over the past two decades has significantly improved survival rates for myeloma patients. The most recent generation of myeloma drugs includes therapeutic monoclonal antibodies (t-mAb), which have shown remarkable efficacy. However, these drugs can interfere with traditional electrophoretic methods used to measure the patient’s monoclonal immunoglobulin (M-Ig), making patient monitoring more challenging. Therefore, alternative laboratory methods that address the limitations of these conventional approaches are needed. Oxford University Hospitals (Oxford, UK), in collaboration with other institutions, is leading the investigation into a new monitoring method known as quantitative immunoprecipitation-mass spectrometry (QIP-MS). The research team will assess whether QIP-MS can predict and detect relapse earlier than current methods in patients with high-risk myeloma participating in the Myeloma XV RADAR trial. This trial involves analyzing bone marrow samples to determine the most effective treatments for myeloma and aims to measure small amounts of myeloma cells, referred to as minimal residual disease (MRD), that may persist after initial treatment.

Previous research has shown that QIP-MS is clinically useful as a first-line screening tool for investigating monoclonal gammopathy, offering higher sensitivity and resolution than the standard methods currently in use. Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are commonly used to detect M-proteins in multiple myeloma patients. However, SPEP and SIFE are not sufficiently sensitive to detect low levels of M-proteins, which may still be clinically significant. QIP-MS, on the other hand, allows for the identification of M-proteins in patients with multiple myeloma who are otherwise in complete remission, and could be ideal for evaluating MRD in peripheral blood. One significant advantage of QIP-MS is that it uses blood samples rather than bone marrow, which, if proven to be more sensitive, would reduce the need for painful procedures during regular monitoring for patients.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.